None listed
Conditions
Brief summary
AI can be used to improve the health and well-being of the elderly. Social isolation and cognitive decline are common challenges among people with dementia. Argoli is a virtual companion designed to provide meaningful conversations, memory-stimulating activities, and support for loved ones, including the elderly, lonely individuals, and those with dementia. The purpose of this study is to evaluate the effectiveness of Argoli in improving the cognitive engagement and emotional well-being of patients with dementia in the context of biochemical changes in dopaminergic system.
Interventions
The pilot study will involve 45 participants (men and women) with early and moderate stage dementia (diagnosed) and healthy subjects between the ages of 55 and 85. The subjects will be divided into 3 groups: randomly patients with early and moderate dementia into two groups (intervention group who use the Argoli app and control group who don't use the Argoli app) and healthy subjects. For a period of 8 weeks, participants will use the Argoli app (Argoli group) daily for 1 hour/day (2x30 minutes)
The pilot study will involve 45 participants (men and women) with early and moderate stage dementia (diagnosed) and healthy subjects between the ages of 55 and 85. The subjects will be divided into 3 groups: randomly patients with early and moderate dementia into two groups (intervention group who use the Argoli app and control group who don't use the Argoli app) and healthy subjects. For a period of 8 weeks, participants will use the Argoli app (Argoli group) daily for 1 hour/day (2x30 minutes) and maintain their current lifestyle (control group and healthy group). Prior to the study, baseline anthropometric measurements will be taken using InBody or DEXA (Dual-energy X-ray Absorptiometry). Pre- and post-intervention subjects will undergo a Mini-mental State exemination (MMSE), Clock-Drawing Test and Self-Administered Gerocognitive Exam (SAGE). Patients with results that indicate mild to moderate dementia will be classified into the intervention group. Before and after the intervention, a blood draw will be performed for biochemical determinations. Argoli is an AI-first health tech platform. As a platform that processes sensitive personal and conversational data, Argoli places the highest priority on security, privacy, and transparency. The study will use Lenovo Tab (TB311XU) 10.1" tablets with the Argoli application installed by researchers. Users and caregivers can: view and manage stored data, delete accounts and related data permanently, export interaction summaries or activity insights. Researchers will have access to app analytics. A conversation using a chatbot (a generated human avatar) and facilitating dialogue between the patient and the avatar. The app provides informational and educational content tailored to the user’s interests in audio format (i.e., conversations). The mode of content delivery: interactive activities.
Sponsors
Ministry of Science and Higher Education
Study design
Allocation
Randomised controlled trial
Intervention model
Other
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Caregiver, Outcomes Assessor)
Eligibility
Sex/Gender
All
Age
55 Years to 85 Years
Healthy volunteers
Yes
Inclusion criteria
The patients diagnosed with early-onset (mild) and moderate dementia, healthy volunteers, male and female 55-85 years old, voluntary consent for examination
Exclusion criteria
Patients who have not been diagnosed with early (mild) and moderate dementia, the patients with severe decrease in cognitive function, health contraindications, lack of voluntary consent, Patients with incapacitation.
Outcome results
None listed